Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.5 PLN | -0.70% | +1.85% | -13.91% |
Sales 2024 * | 152M 38.15M | Sales 2025 * | 218M 54.66M | Capitalization | 1.14B 288M |
---|---|---|---|---|---|
Net income 2024 * | -161M -40.46M | Net income 2025 * | -119M -29.9M | EV / Sales 2024 * | 7.05 x |
Net cash position 2024 * | 73.62M 18.5M | Net Debt 2025 * | 18.41M 4.63M | EV / Sales 2025 * | 5.35 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | -0.70% | ||
1 week | +1.85% | ||
1 month | -9.84% | ||
3 months | -17.36% | ||
6 months | -11.61% | ||
Current year | -13.91% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 49.5 | -0.70% | 2,192 |
24-05-08 | 49.85 | -2.25% | 2,291 |
24-05-07 | 51 | -1.54% | 1,786 |
24-05-06 | 51.8 | +6.58% | 5,235 |
24-05-02 | 48.6 | -1.82% | 3,378 |
Delayed Quote Warsaw S.E., May 09, 2024 at 11:55 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.91% | 288M | |
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- RVU Stock